11.03.2013 - Genmab's antibody drug inclacumab significantly reduces damage to the heart muscle during angioplasty, Canadian researchers reported at the ACC Meeting.
In patients with acute coronary syndrome (ACS), who were treated by opening the blocked artery (Angioplasty/Percutaneous Coronary Intervention, PCI), Inclacumab (RO4905417, RG1512) helped significantly to lower the levels of a biomarker clinically used to diagnose heart attacks. A single shot of the human anti-inflammatory antibody, which is co-developed by Genmab and Roche, reduced Troponin I levels by 24%, said Principal Investigator Dr. Jean-Claude Tardif from University of Montreal at the international meeting of the American College of Cardiology (ACC) on 10 March.
"Inclacumab could indeed become an integral part of the therapeutic arsenal of modern cardiology if we can reproduce these results in subsequent studies", said the Director of the Research Centre at the Montreal Heart Institute. "We could use the drug for a broader patient population, or for all patients who present with a heart attack, but this will require further study." The human antibody targets P-selectin, a molecule which plays an important role in sending white blood cells to the site of an injury during inflammation.
The Phase II trial conducted by Roche involved 530 patients with myocardial infarction who were randomised to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg, or placebo 1 to 24 hours before angioplasty. Markers for heart damage were then measured at 8, 16 and 24 hours after angioplasty.
23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.
21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.